CCA
ALBO

Column Capital Advisors’s Albireo Pharma Inc ALBO Stock Holding History

Column Capital Advisors’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-186
Closed -$3K – 933
2020
Q1 		$3K Buy
+186
New +$4.09K ﹤0.01% 553

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Column Capital Advisors's ALBO Position: Q2 2020 in Review

Column Capital Advisors sold out of Albireo Pharma Inc (ALBO) in Q2 2020, closing a stake of 186 shares — an estimated $3K sold.

Column Capital Advisors first reported a position in ALBO in Q1 2020 and held it in 1 quarter. The position peaked at $3K in Q1 2020. 82 funds tracked by Wall St. Rank hold ALBO as of Q2 2020.

  • Column Capital Advisors reported no remaining Albireo Pharma Inc position as of Q2 2020 after selling out during the quarter.
  • Column Capital Advisors sold 186 Albireo Pharma Inc shares in Q2 2020, an estimated $3K.
  • Column Capital Advisors first reported a position in Albireo Pharma Inc in Q1 2020 and held it in 1 quarter.
  • Column Capital Advisors's Albireo Pharma Inc position peaked at $3K in Q1 2020.
  • 82 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q2 2020.

Based on Column Capital Advisors's 13F filing for Q2 2020, filed 12 Aug 2020.